Lu AG06466 for Multiple Sclerosis

"The trial is currently recruiting 78 individuals with multiple sclerosis, aged between 18 and 70. To be eligible, patients must have a diagnosis of MS as per the 2017 McDonald criteria; have stable symptoms (with no relapses or steady Expanded Disability Status Scale [EDSS] score) over 6 months prior to screening; experience spasticity for 90 days before being screened; not change any medications or non-pharmacological treatments meant to manage their condition in the past 30 days leading up to screening; demonstrate walking impairments caused by lower limb spasticity."

"Our assessment of Lu AG06466's safety landed on a score of 1 as it is currently in the first stage of clinical trials and has limited data backing its efficacy."

"The trial's sponsor, H. Lundbeck A/S, seeks 78 patients with matching inclusion criteria to fully operationalize the study. Two of the sites are Johns Hopkins University located in Denver and Mountain View Clinical Research situated in Saint Louis."

"Affirmative. According to clinicaltrials.gov, the study began recruiting on September 27th 2021 and has recently been updated on October 10 2022. 78 participants are necessary between 5 distinct medical centres."

"This clinical trial has 5 enrolment sites, including Johns Hopkins University in Denver, Mountain View Clinical Research in Saint Louis, and Washington University School of Medicine in Las Vegas. Additionally, there are two other recruiting centres across the country."

"According to the trial's specifications, individuals aged 18-70 may be eligible for enrollment."